UnknownEarly Phase 1NCT04264078

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Studying Extranodal nasal NK/T cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xinqiao Hospital of Chongqing
Principal Investigator
Xi Zhang, MD
Xinqiao Hospital of Chongqing
Intervention
CD7 UCAR-T cells(biological)
Enrollment
30 target
Eligibility
18-70 years · All sexes
Timeline
2021 – 2023

Study locations (1)

Collaborators

Gracell Biotechnologies (Shanghai) Co., Ltd. · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · The Second Affiliated Hospital of Chongqing Medical University · The Affiliated Hospital Of Guizhou Medical University · Central South University · First Affiliated Hospital of Kunming Medical University · The General Hospital of Western Theater Command · Second Affiliated Hospital of Xi'an Jiaotong University · Nanfang Hospital, Southern Medical University · Fujian Medical University Union Hospital · The First Affiliated Hospital of Anhui Medical University · Tang-Du Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04264078 on ClinicalTrials.gov

Other trials for Extranodal nasal NK/T cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Extranodal nasal NK/T cell lymphoma →

← Back to all trials